Kidney Cancer Clinical Trial

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

Summary

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

View Full Description

Full Description

This is a phase 2 pragmatic study at a single site that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary endpoint is disease control at 3 months, defined as continuation in systemic cancer therapy without any changes or permanent discontinuation for 3 months following first day of ablative local therapy. Participants will receive ablative local therapy per standard practices in addition to their systemic therapy and will be followed for up to 5 years following ablative local therapy. Participants will be assigned stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy per the discretion of treating radiation oncologist and/or interventional radiologist.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies:

Cohort A: prostate cancer
Cohort B: urothelial carcinoma
Cohort C: renal cell carcinoma
Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Age ≥18 years at time of consent.
Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.
≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. [Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment]
≤ 5 progressing or new metastatic lesions.
All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.

Exclusion Criteria:

Medical comorbidities precluding locally ablative therapies.
History of treatment related toxicities that limit or prohibit application of locally ablative therapies.
Progressing intracranial lesions.

Study is for people with:

Kidney Cancer

Estimated Enrollment:

150

Study ID:

NCT06101290

Recruitment Status:

Recruiting

Sponsor:

University of California, Davis

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of California, Davis
Sacramento California, 95817, United States More Info
Selina Laqui
Contact
916-734-0565
[email protected]
Mamta Parikh, MD, MS
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Estimated Enrollment:

150

Study ID:

NCT06101290

Recruitment Status:

Recruiting

Sponsor:


University of California, Davis

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.